匹莫范色林与安慰剂治疗阿尔茨海默病精神病的安全性和有效性评估:一项2期随机安慰剂对照双盲研究
这项2期随机双盲安慰剂对照研究纳入181例阿尔茨海默病精神病患者,评估匹莫范色林(每日34 mg)与安慰剂的疗效和安全性。主要终点第6周NPI-NH精神病评分变化,匹莫范色林组-3.76分 vs 安慰剂组-1.93分(均差-1.84,95%CI -3.64至-0.04;p=0.045),达统计学显著;但第12周无显著优势(治疗差-0.51,95%CI -2.23至1.21;p=0.561)。常见不良事件为跌倒、尿路感染和激越。
要点
- 第6周NPI-NH精神病评分变化匹莫范色林组-3.76分 vs 安慰剂组-1.93分,均差-1.84(95%CI -3.64至-0.04;p=0.045)。
- 第12周总体人群未见匹莫范色林较安慰剂的显著优势(治疗差-0.51,95%CI -2.23至1.21;p=0.561)。
- 常见不良事件为跌倒(23% vs 23%)、尿路感染(22% vs 28%)、激越(21% vs 14%)。
核心结论
- 匹莫范色林在第6周主要终点对阿尔茨海默病精神病显示疗效,耐受性可接受,对认知无负面影响。
- 进一步随访至第12周未显示匹莫范色林较安慰剂的显著优势。
研究设计与样本
- 2期随机双盲安慰剂对照研究,单中心(含英国多家附属养老院站点)。
- 纳入181例50岁及以上可能或很可能阿尔茨海默病伴精神病性症状患者,按1:1随机分配接受12周口服匹莫范色林(每日两片17 mg)或安慰剂。
- 随机化采用区组大小为4的置换区组,按基线MMSE总分(<6或≥6)和NPI-NH精神病评分(<12或≥12)分层。
- 主要终点为改良意向治疗人群中第6周NPI-NH精神病评分较基线的平均变化。
主要发现
- 基线NPI-NH精神病总评分均值:匹莫范色林组9.5(SD 4.8),安慰剂组10.0(SD 5.6)。
- 第6周NPI-NH精神病评分平均变化:匹莫范色林组-3.76分(SE 0.65) vs 安慰剂组-1.93分(SE 0.63);均差-1.84(95%CI -3.64至-0.04),Cohen's d=-0.32;p=0.045。
- 第12周总体人群治疗差-0.51(95%CI -2.23至1.21);p=0.561,未见显著优势。
- 常见不良事件:跌倒(匹莫范色林组21/90例[23%] vs 安慰剂组21/91例[23%])、尿路感染(20/90例[22%] vs 25/91例[28%])、激越(19/90例[21%] vs 13/91例[14%])。
- 因不良事件停药:匹莫范色林组8例(9%) vs 安慰剂组11例(12%);两组均未观察到对认知或运动功能的损害效应。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pimavanserin is a selective 5-HT2A receptor inverse agonist and antagonist approved in the USA for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. No safe or effective pharmacological treatment is approved for psychosis in patients with Alzheimer's disease. Therefore, we aimed to evaluate the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis. METHODS: We did a phase 2, randomised, double-blind, placebo-controlled, single-centre (with multiple affiliated nursing home sites across the UK) study. We included participants of either sex who were aged 50 years or older with possible or probable Alzheimer's disease and psychotic symptoms including visual or auditory hallucinations, delusions, or both. Participants were randomly assigned (1:1) to 12 weeks of oral treatment with either pimavanserin (two 17 mg tablets daily) or placebo, with use of permuted block sizes of four and stratified by baseline Mini-Mental State Examination (MMSE) total score (<6 or ≥6) and Neuropsychiatric Inventory-Nursing Home version (NPI-NH) psychosis score (<12 or ≥12). Participants, caregivers, the study sponsor, and study personnel at the clinic site were masked to treatment assignment. The primary endpoint was mean change from baseline to week 6 in the NPI-NH psychosis score for pimavanserin versus placebo in the modified intention-to-treat population. Sustained benefit and safety of pimavanserin were assessed through week 12. This study is registered at ClinicalTrials.gov, number NCT02035553. FINDINGS: Between Jan 16, 2014, and Oct 27, 2016, 345 participants across 133 nursing homes were screened, of whom 181 were randomly assigned treatment (n=90 pimavanserin and n=91 placebo). 178 participants were included in the modified intention-to-treat population. Mean total baseline NPI-NH psychosis scores were 9·5 (SD 4·8) for the pimavanserin group and 10·0 (5·6) for the placebo group. Mean change in the NPI-NH psychosis score at week 6 was -3·76 points (SE 0·65) for pimavanserin and -1·93 points (0·63) for placebo (mean difference -1·84 [95% CI -3·64 to -0·04], Cohen's d=-0·32; p=0·045). By week 12, no significant advantage for pimavanserin versus placebo was observed for the overall study population (treatment difference -0·51 [95% CI -2·23 to 1·21]; p=0·561). Common adverse events were falls (21 [23%] of 90 participants in the pimavanserin group vs 21 [23%] of 91 in the placebo group), urinary tract infections (20 [22%] vs 25 [28%]), and agitation (19 [21%] vs 13 [14%]). Eight (9%) participants on pimavanserin and 11 (12%) on placebo discontinued treatment because of adverse events. No detrimental effect was observed on cognition or motor function in either group. INTERPRETATION: Pimavanserin showed efficacy in patients with Alzheimer's disease psychosis at the primary endpoint (week 6) with an acceptable tolerability profile and without negative effect on cognition. Further follow-up to week 12 did not show significant advantage for pimavanserin versus placebo. FUNDING: ACADIA Pharmaceuticals.
引用
- Ballard C, Banister C, Khan Z, et al. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. Lancet Neurol. 2018. PMID: 29452684. doi:10.1016/S1474-4422(18)30039-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。